- Home
- All Stock List
- NSE
- Senores Pharmaceuticals Ltd Share Price
Senores Pharmaceuticals Ltd Share Price – NSE / BSE
Pharmaceuticals, Small Cap
570.60
-16.80 (-2.86%)
-
Underperforms Index
0%
Return (1Y)
Underperformed Nifty 50 by 5.34%
-
More Volatile
4.55%
Standard Deviation (1Y)
Higher than Nifty 50 by 3.66%
-
Inconsistent Performer
3/4
Months
underperformed Nifty 50
-
AxisDirect View
No View
665
435
News & Announcements
-
Senores Pharma jumps on inking pact to acquire 14 ANDAs from Dr. Reddy’s Labs
04 - Mar - 2025 12:00 | 27 days ago
According to an exchange filing, the basket of acquired ANDAs consists of 13 USFDA-approved applications and one that is pending approval.
The addressable market opportunity for these ANDAs in the U.S. is estimated at approximately USD 421 million (MAT December 2024), as per IQVIA, and around USD 1.13 billion (MAT September 2024), according to specialty data aggregator Symphony.
The acquisition will be funded through the proceeds raised from Senores Pharmaceuticals' Initial Public Offer (IPO), in line with the objectives outlined in the Red Herring Prospectus.
Swapnil Shah, Managing Director, Senores Pharmaceuticals, said, “We are glad to announce the acquisition of a basket of products from Dr. Reddy's. It spans across various therapeutic areas with growing consumption. The portfolio consists of controlled substances and general categories of products.
These products can be distributed through multiple/diverse channels, with large requirements in government, retail and specialty clinics.
This portfolio of products significantly increases our product offering in the US, and it also has a significant value in other regulated and semi-regulated markets of the world.”
Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.
Shares of Dr. Reddy's Laboratories rose 0.05% to Rs 1,120.40 on the BSE.
Powered by Capital Market - Live News
-
Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories and its applicable affiliates.
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA.
The addressable opportunity of the acquired ANDAs in the USA is approx. USD 421 Million (MAT December 2024) as per IQVIA and ~ approx USD 1.13 Billion (MAT September 2024)# as per the specialty data aggregator Symphony.
The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Powered by Capital Market - Live News
-
Senores Pharma begins Greenfield API manufacturing facility in Gujarat
27 - Feb - 2025 12:00 | 32 days ago
The facility spans approximately 230,000 sq. ft. and has an installed capacity of 100 metric tons per year. This marks their second API manufacturing plant, significantly enhancing their existing API manufacturing capabilities.
Swapnil Shah, MD, SenoresPharmaceuticals, said, “We are delighted to commence operations at our Greenfield state-of-the-art API facility at Mehsana. Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the regulated markets, especially in the CDMO/CMO business.”
Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.
Shares of Senores Pharma rose 0.34% to Rs 550.40 on the BSE.
Powered by Capital Market - Live News
-
Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories and its applicable affiliates.
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA.
The addressable opportunity of the acquired ANDAs in the USA is approx. USD 421 Million (MAT December 2024) as per IQVIA and ~ approx USD 1.13 Billion (MAT September 2024)# as per the specialty data aggregator Symphony.
The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Powered by Capital Market - Live News
-
Senores Pharma begins Greenfield API manufacturing facility in Gujarat
27 - Feb - 2025 12:00 | 32 days ago
The facility spans approximately 230,000 sq. ft. and has an installed capacity of 100 metric tons per year. This marks their second API manufacturing plant, significantly enhancing their existing API manufacturing capabilities.
Swapnil Shah, MD, SenoresPharmaceuticals, said, “We are delighted to commence operations at our Greenfield state-of-the-art API facility at Mehsana. Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the regulated markets, especially in the CDMO/CMO business.”
Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.
Shares of Senores Pharma rose 0.34% to Rs 550.40 on the BSE.
Powered by Capital Market - Live News
-
Senores Pharmaceuticals has commenced manufacturing activities at its greenfield active pharmaceutical ingredient (API) plant at Mehsana, Gujarat.
Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, this is Senores' second API manufacturing facility.
Powered by Capital Market - Live News
-
Senores Pharma jumps on inking pact to acquire 14 ANDAs from Dr. Reddy’s Labs
04 - Mar - 2025 12:00 | 27 days ago
According to an exchange filing, the basket of acquired ANDAs consists of 13 USFDA-approved applications and one that is pending approval.
The addressable market opportunity for these ANDAs in the U.S. is estimated at approximately USD 421 million (MAT December 2024), as per IQVIA, and around USD 1.13 billion (MAT September 2024), according to specialty data aggregator Symphony.
The acquisition will be funded through the proceeds raised from Senores Pharmaceuticals' Initial Public Offer (IPO), in line with the objectives outlined in the Red Herring Prospectus.
Swapnil Shah, Managing Director, Senores Pharmaceuticals, said, “We are glad to announce the acquisition of a basket of products from Dr. Reddy's. It spans across various therapeutic areas with growing consumption. The portfolio consists of controlled substances and general categories of products.
These products can be distributed through multiple/diverse channels, with large requirements in government, retail and specialty clinics.
This portfolio of products significantly increases our product offering in the US, and it also has a significant value in other regulated and semi-regulated markets of the world.”
Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.
Shares of Dr. Reddy's Laboratories rose 0.05% to Rs 1,120.40 on the BSE.
Powered by Capital Market - Live News
-
Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories and its applicable affiliates.
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA.
The addressable opportunity of the acquired ANDAs in the USA is approx. USD 421 Million (MAT December 2024) as per IQVIA and ~ approx USD 1.13 Billion (MAT September 2024)# as per the specialty data aggregator Symphony.
The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Powered by Capital Market - Live News
-
Senores Pharma begins Greenfield API manufacturing facility in Gujarat
27 - Feb - 2025 12:00 | 32 days ago
The facility spans approximately 230,000 sq. ft. and has an installed capacity of 100 metric tons per year. This marks their second API manufacturing plant, significantly enhancing their existing API manufacturing capabilities.
Swapnil Shah, MD, SenoresPharmaceuticals, said, “We are delighted to commence operations at our Greenfield state-of-the-art API facility at Mehsana. Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the regulated markets, especially in the CDMO/CMO business.”
Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.
Shares of Senores Pharma rose 0.34% to Rs 550.40 on the BSE.
Powered by Capital Market - Live News
-
Senores Pharmaceuticals has commenced manufacturing activities at its greenfield active pharmaceutical ingredient (API) plant at Mehsana, Gujarat.
Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, this is Senores' second API manufacturing facility.
Powered by Capital Market - Live News
-
Senores Pharma jumps on inking pact to acquire 14 ANDAs from Dr. Reddy’s Labs
04 - Mar - 2025 12:00 | 27 days ago
According to an exchange filing, the basket of acquired ANDAs consists of 13 USFDA-approved applications and one that is pending approval.
The addressable market opportunity for these ANDAs in the U.S. is estimated at approximately USD 421 million (MAT December 2024), as per IQVIA, and around USD 1.13 billion (MAT September 2024), according to specialty data aggregator Symphony.
The acquisition will be funded through the proceeds raised from Senores Pharmaceuticals' Initial Public Offer (IPO), in line with the objectives outlined in the Red Herring Prospectus.
Swapnil Shah, Managing Director, Senores Pharmaceuticals, said, “We are glad to announce the acquisition of a basket of products from Dr. Reddy's. It spans across various therapeutic areas with growing consumption. The portfolio consists of controlled substances and general categories of products.
These products can be distributed through multiple/diverse channels, with large requirements in government, retail and specialty clinics.
This portfolio of products significantly increases our product offering in the US, and it also has a significant value in other regulated and semi-regulated markets of the world.”
Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.
Shares of Dr. Reddy's Laboratories rose 0.05% to Rs 1,120.40 on the BSE.
Powered by Capital Market - Live News
-
Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories and its applicable affiliates.
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA.
The addressable opportunity of the acquired ANDAs in the USA is approx. USD 421 Million (MAT December 2024) as per IQVIA and ~ approx USD 1.13 Billion (MAT September 2024)# as per the specialty data aggregator Symphony.
The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Powered by Capital Market - Live News
-
Senores Pharma begins Greenfield API manufacturing facility in Gujarat
27 - Feb - 2025 12:00 | 32 days ago
The facility spans approximately 230,000 sq. ft. and has an installed capacity of 100 metric tons per year. This marks their second API manufacturing plant, significantly enhancing their existing API manufacturing capabilities.
Swapnil Shah, MD, SenoresPharmaceuticals, said, “We are delighted to commence operations at our Greenfield state-of-the-art API facility at Mehsana. Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the regulated markets, especially in the CDMO/CMO business.”
Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.
Shares of Senores Pharma rose 0.34% to Rs 550.40 on the BSE.
Powered by Capital Market - Live News
-
Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories and its applicable affiliates.
The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA.
The addressable opportunity of the acquired ANDAs in the USA is approx. USD 421 Million (MAT December 2024) as per IQVIA and ~ approx USD 1.13 Billion (MAT September 2024)# as per the specialty data aggregator Symphony.
The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.
Powered by Capital Market - Live News
-
Senores Pharma begins Greenfield API manufacturing facility in Gujarat
27 - Feb - 2025 12:00 | 32 days ago
The facility spans approximately 230,000 sq. ft. and has an installed capacity of 100 metric tons per year. This marks their second API manufacturing plant, significantly enhancing their existing API manufacturing capabilities.
Swapnil Shah, MD, SenoresPharmaceuticals, said, “We are delighted to commence operations at our Greenfield state-of-the-art API facility at Mehsana. Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the regulated markets, especially in the CDMO/CMO business.”
Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.
The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.
Shares of Senores Pharma rose 0.34% to Rs 550.40 on the BSE.
Powered by Capital Market - Live News
-
Senores Pharmaceuticals has commenced manufacturing activities at its greenfield active pharmaceutical ingredient (API) plant at Mehsana, Gujarat.
Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, this is Senores' second API manufacturing facility.
Powered by Capital Market - Live News
Stock Trivia
FII shareholding in Senores Pharmaceuticals Ltd has decreased by -22.84% since past 3 Months
Senores Pharmaceuticals Ltd has the Lowesr P/B ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
FII shareholding in Senores Pharmaceuticals Ltd has decreased by -22.84% since past 3 Months
MF shareholding in Senores Pharmaceuticals Ltd has decreased by -11.21% since past 3 Months
Senores Pharmaceuticals Ltd has the Lowesr P/E ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
Senores Pharmaceuticals Ltd has the Lowesr P/B ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
FII shareholding in Senores Pharmaceuticals Ltd has decreased by -22.84% since past 3 Months
Senores Pharmaceuticals Ltd has the Lowesr P/B ratio according to FY 202403 data among stocks in Pharmaceuticals Sector
